



## **TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial**

June 9, 2026

*82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11)*

*Potential registration-directed Phase 2 trial utilizes novel sequential treatment approach designed to combine rapid symptom control of FcRn inhibition with sustained disease modification of B-cell depletion therapy*

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the "Company" or "TG Therapeutics"), today announced positive topline Phase 1 data for BRIUMVI in patients with myasthenia gravis (MG) and the initiation of a Phase 2 clinical trial evaluating BRIUMVI as a maintenance therapy following induction with efgartigimod in adult patients with MG.

Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics, stated, "We are pleased to report positive data from 11 patients with myasthenia gravis treated with subcutaneous BRIUMVI in our Phase 1 study. These encouraging results support continued development of BRIUMVI in MG and also mark an important milestone in expanding the potential utility of BRIUMVI beyond Multiple Sclerosis."

Mr. Weiss continued, "We are also excited to initiate this potentially registration-directed Phase 2 study evaluating a novel sequential treatment approach in myasthenia gravis. By combining the rapid clinical benefit associated with FcRn inhibition with the durable disease control provided by B-cell depletion through BRIUMVI, we believe this strategy has the potential to establish a differentiated treatment paradigm in MG, while reducing the treatment burden associated with chronic FcRn therapy."

### **PHASE 1 RESULTS- MG COHORT**

#### **Design:**

In an ongoing Phase 1 study evaluating subcutaneous BRIUMVI, 11 patients with AChR-antibody-positive MG (mean age 74, 73% male) received subcutaneous BRIUMVI across cohorts that demonstrated exposure at least equivalent to the approved IV BRIUMVI regimen. At baseline, patients had clinically meaningful disease burden, with mean baseline Myasthenia Gravis Activities of Daily Living (MG-ADL) of 8.24 (range 6 – 13) and mean baseline Quantitative Myasthenia Gravis (QMG) score of 12.0 (range 7 – 22).

#### **Key Data Highlights:**

- Consistent reductions from baseline were observed across all myasthenia gravis outcome measures over time following treatment with subcutaneous BRIUMVI
- At Week 24, 82% of patients achieved the Minimal Clinically Important Difference (MCID) in MG-ADL, defined as a decrease of  $\geq 2$ , with a median time to MCID of 30 days
- Overall, a mean 4.6 point improvement in MG-ADL was observed at Week 24
- Subcutaneous BRIUMVI was generally well tolerated, with a safety profile appearing consistent with the established safety profile of IV BRIUMVI in patients with multiple sclerosis

Full results from this study are expected to be presented at a future medical meeting.

#### **BRIUMVI PHASE 2 TRIAL DESIGN IN MG**

A Phase 2 trial has been initiated to evaluate the efficacy and safety of BRIUMVI in maintaining clinical response in patients with myasthenia gravis (MG) who initially respond to treatment with the FcRn inhibitor efgartigimod. The study is designed to assess whether BRIUMVI can extend the clinical benefit achieved with FcRn inhibition following a single induction cycle of efgartigimod, potentially reducing the need for repeated FcRn treatment to maintain disease control.

The Phase 2 trial is expected to enroll approximately 120 patients. All enrolled patients will first receive a single induction cycle of efgartigimod, consisting of four weekly infusions. Patients who achieve a clinical response, defined as at least a 2-point improvement in MG-ADL score, will then be randomized 1:1 to receive either BRIUMVI or placebo during a 24-week randomized controlled period.

The study will initially utilize the approved intravenous BRIUMVI dosing regimen, with subcutaneous BRIUMVI administration to be incorporated at a later stage following completion of pharmacokinetic bridging studies currently underway in multiple sclerosis.

The primary endpoint is time to clinical worsening, defined as a  $\geq 2$ -point increase in MG-ADL score from baseline or a myasthenic crisis requiring hospitalization.

Following completion of the randomized period, all patients will be eligible to enter a 72-week open-label extension evaluating treatment with

BRIUMVI.

## **ABOUT MYASTHENIA GRAVIS**

Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by muscle weakness and fatigue caused by autoantibodies targeting the neuromuscular junction. Despite available therapies, many patients experience relapses or require frequent treatment, highlighting the need for more durable treatment approaches.

## **ABOUT BRIUMVI® (ublituximab-xiyy) 150 mg/6 mL Injection for IV**

BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses.

BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in several countries outside of the U.S. for the treatment of adult patients with RMS with active disease defined by clinical or imaging features.

A list of authorized specialty distributors can be found at [www.briumvi.com](http://www.briumvi.com).

## **IMPORTANT SAFETY INFORMATION**

**Contraindications: BRIUMVI is contraindicated in patients with:**

- Active Hepatitis B Virus infection
- A history of life-threatening infusion reaction to BRIUMVI

## **WARNINGS AND PRECAUTIONS**

**Infusion Reactions:** BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within 24 hours of the first infusion. 0.6% of BRIUMVI-treated patients experienced infusion reactions that were serious, some requiring hospitalization.

Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.

**Infections:** Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was 56% compared to 54% in teriflunomide-treated patients. The rate of serious infections was 5% compared to 3% respectively. There were 3 infection-related deaths in BRIUMVI-treated patients. The most common infections in BRIUMVI-treated patients included upper respiratory tract infection (45%) and urinary tract infection (10%). Delay BRIUMVI administration in patients with an active infection until the infection is resolved.

Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI.

**Hepatitis B Virus (HBV) Reactivation:** HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HB surface antigen (HBsAg) and anti-HB tests. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment.

**Progressive Multifocal Leukoencephalopathy (PML):** PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. JCV infection resulting in PML has been observed in patients treated with anti-CD20 antibodies, including BRIUMVI, and other MS therapies.

If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.

MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis.

If PML is confirmed, treatment with BRIUMVI should be discontinued.

**Vaccinations:** Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines, at least 4 weeks and, whenever possible, at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion.

**Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy:** In infants of mothers exposed to BRIUMVI during pregnancy, assess

B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19<sup>+</sup> B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.

**Fetal Risk:** Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose.

**Reduction in Immunoglobulins:** As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in 0.6% of BRIUMVI-treated patients compared to none of the patients treated with teriflunomide in RMS clinical trials. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy, until B-cell repletion. Consider discontinuing BRIUMVI therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins.

**Liver Injury:** Clinically significant liver injury, without findings of viral hepatitis, has been reported in the postmarketing setting in patients treated with anti-CD20 B-cell depleting therapies approved for the treatment of MS, including BRIUMVI. Signs of liver injury, including markedly elevated serum hepatic enzymes with elevated total bilirubin, have occurred from weeks to months after administration.

Patients treated with BRIUMVI found to have an alanine aminotransaminase (ALT) or aspartate aminotransferase (AST) greater than 3x the upper limit of normal (ULN) with serum total bilirubin greater than 2x ULN are potentially at risk for severe drug-induced liver injury.

Obtain liver function tests prior to initiating treatment with BRIUMVI, and monitor for signs and symptoms of any hepatic injury during treatment. Measure serum aminotransferases, alkaline phosphatase, and bilirubin levels promptly in patients who report symptoms that may indicate liver injury, including new or worsening fatigue, anorexia, nausea, vomiting, right upper abdominal discomfort, dark urine, or jaundice. If liver injury is present and an alternative etiology is not identified, discontinue BRIUMVI.

**Most Common Adverse Reactions:** The most common adverse reactions in RMS trials (incidence of at least 10%) were infusion reactions and upper respiratory tract infections.

Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit [www.briumvi.com](http://www.briumvi.com).

The full Summary of Product Characteristics approved in the European Union (EU) for BRIUMVI can be found here: [Briumvi | European Medicines Agency \(europa.eu\)](http://Briumvi|EuropeanMedicinesAgency.europa.eu).

#### **ABOUT BRIUMVI PATIENT SUPPORT in the U.S.**

BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at [www.briumvipatientsupport.com](http://www.briumvipatientsupport.com).

#### **ABOUT TG THERAPEUTICS**

TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiyy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by several foreign nations for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit [www.tgtherapeutics.com](http://www.tgtherapeutics.com), and follow us on X (formerly Twitter) [@TGTherapeutics](https://twitter.com/TGTherapeutics) and on [LinkedIn](https://www.linkedin.com/company/tgtherapeutics).

BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

#### **Cautionary Statement**

This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below.

Such forward looking statements include but are not limited to statements regarding our plans, business strategies and operations related to the commercialization of BRIUMVI® (ublituximab-xiyy) for RMS in the United States, or any jurisdictions outside of the United States; anticipated healthcare professional (HCP) and patient acceptance and use of BRIUMVI for the approved indications; expectations of future revenue for BRIUMVI, or TG expenses or profit estimates or targets; expectations and timing for our subcutaneous BRIUMVI program, including feasibility, approvability and commercial acceptance, expectations and timing for our ENHANCE Phase 3b trial combining day 1 and day 15 doses, including, feasibility, approvability and commercial acceptance and impact on BRIUMVI sales, and expectations and timing for any of our pipeline products or programs, including Azer-cel or BRIUMVI in MG.

Additional factors that could cause our actual results to differ materially include the following: the Company's ability to continue to commercialize BRIUMVI; the risk that trends in prescriptions are not maintained or that prescriptions are not filled; the failure to obtain and maintain payor coverage; the risk that HCP interest in BRIUMVI will not be sustained; the risk that momentum in sales for BRIUMVI will not be sustained during the course of the year; the risk that the commercialization of BRIUMVI does not continue to exceed expectations; the risk that our BRIUMVI revenue targets will not be achieved; the failure to obtain and maintain requisite regulatory approvals, including the risk that the Company fails to satisfy post-approval regulatory requirements, the potential for variations from the Company's projections and estimates about the potential market for BRIUMVI due to a number of factors, including, further limitations that regulators may impose on the required labeling for BRIUMVI (such as modifications, resulting from safety

signals that arise in the post-marketing setting or in the long-term extension study from the ULTIMATE I and II clinical trials); the Company's ability to meet post-approval compliance obligations (on topics including but not limited to product quality, product distribution and supply chain, pharmacovigilance, and sales and marketing); the Company's reliance on third parties for manufacturing, distribution and supply, and other support functions for our clinical and commercial products, including BRIUMVI, and the ability of the Company and its manufacturers and suppliers to produce and deliver BRIUMVI to meet the market demand for BRIUMVI; the risk that any individual patient's clinical experience in the post-marketing setting, or the aggregate patient experience in the post-marketing setting, may differ from that demonstrated in controlled clinical trials such as ULTIMATE I and II; the risk that the Company does not achieve its 2026 development pipeline anticipated milestones or goals in the timeframe projected or at all, including (i) completing a pivotal program for subcutaneous ublituximab, (ii) enrolling patients into a trial evaluating BRIUMVI in MG, or (iii) enrolling patients into a trial evaluating azer-cel; the risk that clinical trial data readouts may be delayed due to a number of factors including enrollment, data collection, data maturity or other factors; the risk that despite positive Phase 1 data projecting a positive outcome, that the Phase 3 subcutaneous BRIUMVI program will not meet the primary endpoint, or if it successfully meets the primary endpoint, still will not lead to the approval of subcutaneous BRIUMVI by the FDA or other regulatory authorities or, if approved, will not achieve commercial acceptance; the risk that, if subcutaneous BRIUMVI is approved and achieves commercial acceptance, the anticipated expansion of the addressable market will not be realized; the risk that the Phase 3b ENHANCE trial despite being successful will not lead to an approval by the FDA or achieve commercial acceptance for a consolidated initiation regimen; the risk that the Phase 2 MG study will not be successful or if successful will not be considered a registrational study; the risk that we will not move forward with the development of BRIUMVI in MG and Azer-Cel following these preliminary studies; the uncertainties generally inherent in research and development, including the risk that the data from Phase 1 studies, including safety and efficacy, may not be replicated in registration directed or Phase 3 studies conducted in larger populations with longer follow-up; regulatory developments, legislative actions, executive orders, including the imposition of tariffs and policy changes in the U.S. and other jurisdictions; and general political, economic and business conditions. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our other filings with the SEC.

Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at [www.tgtherapeutics.com](http://www.tgtherapeutics.com). The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

**CONTACT:**

**Investor Relations**

Email: [ir@tgtxinc.com](mailto:ir@tgtxinc.com)

Telephone: 1.877.575.TGTX (8489), Option 4

**Media Relations**

Email: [media@tgtxinc.com](mailto:media@tgtxinc.com)

Telephone: 1.877.575.TGTX (8489), Option 6